195 related articles for article (PubMed ID: 17068072)
1. Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial.
Gittins NS; Hunter-Blair YL; Matthews JN; Coulthard MG
Arch Dis Child; 2007 Jun; 92(6):499-501. PubMed ID: 17068072
[TBL] [Abstract][Full Text] [Related]
2. Should paediatric central lines be aspirated before use?
Coulthard MG; Skinner R
Arch Dis Child; 2007 Jun; 92(6):517-8. PubMed ID: 17068071
[TBL] [Abstract][Full Text] [Related]
3. Does low-dose heparin maintain central venous access device patency?: a comparison of heparin versus saline during a period of heparin shortage.
Jonker MA; Osterby KR; Vermeulen LC; Kleppin SM; Kudsk KA
JPEN J Parenter Enteral Nutr; 2010; 34(4):444-9. PubMed ID: 20631392
[TBL] [Abstract][Full Text] [Related]
4. Urokinase: new indication. Thrombosed venous and dialysis catheters: when heparin fails. Urokinase clears about 75% of thrombosed venous catheters intended for long-term use with a dose-related increase in the bleeding risk.
Prescrire Int; 2009 Jun; 18(101):118. PubMed ID: 19637430
[No Abstract] [Full Text] [Related]
5. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study.
Choi M; Massicotte MP; Marzinotto V; Chan AK; Holmes JL; Andrew M
J Pediatr; 2001 Jul; 139(1):152-6. PubMed ID: 11445811
[TBL] [Abstract][Full Text] [Related]
6. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP;
J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704
[TBL] [Abstract][Full Text] [Related]
7. Restoration of flow following haemodialysis catheter thrombus. Analysis of rt-PA infusion in tunnelled dialysis catheters.
Davies J; Casey J; Li C; Crowe AV; McClelland P
J Clin Pharm Ther; 2004 Dec; 29(6):517-20. PubMed ID: 15584939
[TBL] [Abstract][Full Text] [Related]
8. Alteplase versus urokinase for occluded hemodialysis catheters.
Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction.
Little MA; Walshe JJ
Am J Kidney Dis; 2002 Jan; 39(1):86-91. PubMed ID: 11774106
[TBL] [Abstract][Full Text] [Related]
10. Effective use of alteplase for occluded tunneled venous catheter in hemodialysis patients.
Mendes ML; Castro JH; Silva TN; Barretti P; Ponce D
Artif Organs; 2014 May; 38(5):399-403. PubMed ID: 24117542
[TBL] [Abstract][Full Text] [Related]
11. Concentration of heparin-locking solution and risk of central venous hemodialysis catheter malfunction.
Thomas CM; Zhang J; Lim TH; Scott-Douglas N; Hons RB; Hemmelgarn BR;
ASAIO J; 2007; 53(4):485-8. PubMed ID: 17667236
[TBL] [Abstract][Full Text] [Related]
12. Alteplase use for malfunctioning central venous catheters correlates with catheter-associated bloodstream infections.
Rowan CM; Miller KE; Beardsley AL; Ahmed SS; Rojas LA; Hedlund TL; Speicher RH; Nitu ME
Pediatr Crit Care Med; 2013 Mar; 14(3):306-9. PubMed ID: 23392362
[TBL] [Abstract][Full Text] [Related]
13. Comparison between standard heparin and tinzaparin for haemodialysis catheter lock.
Malo J; Jolicoeur C; Theriault F; Lachaine J; Senecal L
ASAIO J; 2010; 56(1):42-7. PubMed ID: 20051836
[TBL] [Abstract][Full Text] [Related]
14. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
[TBL] [Abstract][Full Text] [Related]
15. Management of a large organized intraatrial catheter-tip thrombus in a child with acquired immunodeficiency syndrome using escalating tissue plasminogen activator infusions.
Mathur M; Desai N; Sharma J; Rao SP; Goldman GM
Pediatr Crit Care Med; 2005 Jan; 6(1):79-82. PubMed ID: 15636665
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tissue plasminogen activator-antibiotic locks with heparin-antibiotic locks in children with catheter-related bacteraemia.
Onder AM; Chandar J; Simon N; Diaz R; Nwobi O; Abitbol CL; Zilleruelo G
Nephrol Dial Transplant; 2008 Aug; 23(8):2604-10. PubMed ID: 18332071
[TBL] [Abstract][Full Text] [Related]
17. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children.
Jacobs BR; Haygood M; Hingl J
J Pediatr; 2001 Oct; 139(4):593-6. PubMed ID: 11598611
[TBL] [Abstract][Full Text] [Related]
18. [Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients].
Lagasse JP; Bahallah ML; Salem N; Debillon G; Labarrière D; Serve MP; Advenier V; Causse X; Legoux JL
Gastroenterol Clin Biol; 1997; 21(12):919-23. PubMed ID: 9587554
[TBL] [Abstract][Full Text] [Related]
19. Thrombosis of tunneled-cuffed hemodialysis catheters: treatment with high-dose urokinase lock therapy.
Donati G; Colì L; Cianciolo G; La Manna G; Cuna V; Montanari M; Gozzetti F; Stefoni S
Artif Organs; 2012 Jan; 36(1):21-8. PubMed ID: 21848863
[TBL] [Abstract][Full Text] [Related]
20. Use of heparin-coated central venous lines to prevent catheter-related bloodstream infection.
Abdelkefi A; Achour W; Ben Othman T; Ladeb S; Torjman L; Lakhal A; Ben Hassen A; Hsairi M; Ben Abdeladhim A
J Support Oncol; 2007 Jun; 5(6):273-8. PubMed ID: 17624052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
